Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Topical methyl aminolevulinate.

M Asif A Siddiqui1, Caroline M Perry, Lesley J Scott

  • 1Adis International Inc, Yardley, Pennsylvania 19067, USA. demail@adis.com

American Journal of Clinical Dermatology
|April 28, 2004
PubMed
Summary

Methyl aminolevulinate photodynamic therapy (MAL-PDT) effectively treats actinic keratosis and basal cell carcinoma with high response rates. This treatment offers superior or comparable efficacy to existing therapies and excellent cosmetic outcomes with good tolerability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2022
Same author

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2021
Same author

Opicapone: A Review in Parkinson's Disease.

CNS drugs·2021
Same author

Lumasiran: First Approval.

Drugs·2021
Same author

Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2020
Same author

Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2020

Area of Science:

  • Dermatology
  • Oncology
  • Photomedicine

Background:

  • Methyl aminolevulinate (MAL) is a topical photosensitizer used in photodynamic therapy (PDT).
  • PDT is a treatment modality for various skin conditions, including epidermal lesions.

Purpose of the Study:

  • To evaluate the efficacy and safety of Methyl aminolevulinate photodynamic therapy (MAL-PDT) for treating actinic keratosis (AK) and basal cell carcinoma (BCC).

Main Methods:

  • The study utilized a standard MAL-PDT regimen: MAL 160 mg/g applied topically for 3 hours, followed by red light illumination (570-670 nm) at 75 J/cm(2).
  • Efficacy was assessed through complete response rates in randomized, multicenter, phase III clinical trials.
  • Comparisons were made against placebo-PDT, cryotherapy, and excision surgery.

Related Experiment Videos

Main Results:

  • MAL-PDT achieved complete response rates of up to 91% for AK and 97% for BCC.
  • Treatment outcomes were superior to placebo-PDT and comparable to cryotherapy and surgery.
  • Excellent to good cosmetic results were observed, often better than with conventional treatments.
  • Over 75% of treated BCC lesions remained in remission at 12-24 months post-treatment.

Conclusions:

  • MAL-PDT is a highly effective and well-tolerated treatment for AK and BCC.
  • It demonstrates significant efficacy, favorable cosmetic outcomes, and durable remission rates.
  • MAL-PDT represents a valuable therapeutic option for epidermal skin cancers.